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ABSTRACT 
Background
Prompt diagnosis and early treatment prevents disability in POEMS syndrome. Delay in 
diagnosis is common with 55% of patients initially incorrectly diagnosed with Chronic 
Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). Patients are often treated with 
Intravenous Immunoglobulin (IVIG) which is both expensive and ineffective in the treatment of 
POEMS. Testing patients with acquired demyelinating neuropathy with serum vascular 
endothelial growth factor (VEGF) more accurately identifies POEMS syndrome than the current 
standard of care (SOC). Incorporating VEGF testing into screening could prevent misdiagnosis 
and reduce costs.
 
Methods 
We used observed treatment information for patients in the University College London 
Hospital’s (UCLH) POEMS syndrome database (n=100) and from the National Immunoglobulin 
Database to estimate costs associated with incorrect CIDP diagnoses across our cohort. We 
conducted a model-based cost-effectiveness analysis to compare the current diagnostic 
algorithm with an alternative which includes VEGF testing for all patients with an acquired 
demyelinating neuropathy.
 
Results
Treatment associated with an incorrect CIDP diagnosis led to total wasted healthcare 
expenditures of between £808,550 and £1,111,756 across our cohort, with an average cost-per-
POEMS-patient misdiagnosed of £14,701 to £20,214. Introducing mandatory VEGF testing for 
patients with acquired demyelinating neuropathy would lead to annual cost-savings of £107,000 
for the NHS and could prevent misdiagnosis in 16 cases per annum.
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Conclusions
Misdiagnosis in POEMS syndrome results in diagnostic delay, disease progression and 
significant healthcare costs. Introducing mandatory VEGF testing for patients with acquired 
demyelinating neuropathy is a cost-effective strategy allowing for early POEMS diagnosis and 
potentially enabling prompt disease-directed therapy.
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INTRODUCTION 
Polyneuropathy Organomegaly Endocrinopathy Monoclonal-protein (M-protein) and Skin 
Changes (POEMS) syndrome is a rare but treatable cause of acquired peripheral neuropathy. 
Patients present with length dependent sensorimotor neuropathy, with mixed axonal and 
demyelinating features on neurophysiology.[1–4] Fifty-five percent of patients with confirmed 
POEMS are initially misdiagnosed as having Chronic Inflammatory Demyelinating 
Polyradiculoneuropathy (CIDP), and are treated with immunomodulatory therapies including 
steroids, intravenous immunoglobulin (IVIG) and plasma exchange (PLEX).[5] IVIG is ineffective  
and costly (approximately £42.50 per gram in 2020), [6] often requires day case or hospital 
inpatient stays and can result in minor or severe complications. Diagnostic complexity results in 
a median time to POEMS diagnosis of 14 months, by which time over 30% of patients require a 
wheelchair or are bedbound.[5]
POEMS syndrome diagnosis relies on identification of a lambda light chain restricted paraprotein 
in combination with the typical neuropathy as hallmarks of disease.[7] Routine investigations to 
discover a monoclonal protein involve a serum protein electrophoresis (SPEP) and 
immunofixation. We have demonstrated in our UK cohort of 100 patients that the SPEP was 
positive in 55% of cases, and immunofixation in 78%.[5] It is common practice for laboratories to 
perform immunofixation only if a paraprotein is present on SPEP, despite studies indicating the 
superiority sensitivity of immunofixation in detecting low level monoclonal bands missed by 
conventional electrophoresis techniques.[8,9] Although modern high resolution electrophoresis 
can be as sensitive as immunofixation,[10] it is not in widespread use and has not been tested in 
POEMS syndrome cases which classically manifest small but significantly relevant monoclonal 
gammopathies. The data from our clinical cohort demonstrates a critical low level monoclonal 
band would not have been detected in 23% of cases by SPEP methodology only. The disparity 
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in SPEP and immunofixation techniques across laboratories, combined with differences in levels 
of sensitivity results in such tests often being difficult to interpret and rely upon.
Serum vascular endothelial growth factor (VEGF) of >1000pg/ml has high sensitivity (100%) and 
specificity (93%) in the diagnosis of POEMS syndrome, particularly when a demyelinating 
neuropathy and lambda light chain paraprotein present together. Levels are often very high 
(median pre-treatment VEGF levels in our cohort was 3594pg/ml), [5] and although iron deficiency 
anaemia, infection or chronic hypoxic states raise VEGF,[11–16] very high levels found with a 
demyelinating neuropathy and lambda light chain are diagnostic.  This room temperature stable 
serum test can be sent to specialist labs for measurement, costing approximately £50 per 
sample.[17] We argue that an immunofixation and VEGF should be part of routine testing for 
patients presenting with an acquired peripheral neuropathy and with slowd conduction velocities 
on nerve conduction studies, particularly in those with suspected CIDP. 
This study aims to add to the evidence base supporting a change in the polyneuropathy diagnostic 
process to include VEGF, uniquely from a cost-perspective. In particular, the study will estimate:
I. The cost of misdiagnosing POEMS syndrome patients with CIDP; and 
II. The incremental cost-effectiveness ratio of a new POEMS diagnostic pathway. 
METHODS
Our sequential cohort (n=100) was taken from the POEMS syndrome database of University 
College London Hospital’s (UCLH), which includes clinical, diagnostic and treatment data. We 
collected additional data on IVIG treatment from the National Demand Management Programme 
for Immunoglobulin database. [18]
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Costing analysis 
The costing analysis focused on comparing the cost of patients directly diagnosed with POEMS 
syndrome, compared with patients diagnosed with POEMS subsequent to an incorrect CIDP 
diagnosis. For each activity leading up to a confirmed POEMS syndrome diagnosis (Figure 1), we 
estimated the quantity of resources used and multiplied these by their respective unit costs. A list 
of all costing inputs used is included in Supplementary Material I which presents all inputs and 
assumptions in this analysis. 
 
As detailed IVIG treatment data, including number of treatments and IVIG quantity prescribed was 
only available for a sub-set of patients (n=26), we used information from the National 
Immunoglobulin Database to estimate the average cost of IVIG treatment-per-patient, and 
combined this with unit costs of plasma exchange and corticosteroids to estimate the total costs 
associated with an incorrect CIDP diagnosis for each patient. By multiplying average cost-per-
POEMS syndrome patient misdiagnosed with CIDP by the number of misdiagnosed patients, we 
estimated the total cost associated with CIDP misdiagnoses across our cohort, following NICE 
guidelines that is the costs of the excess activities indicated in the pink shaded box in Figure 1.
Cost-effectiveness analysis 
We used decision analytical modelling to compare the cost-effectiveness of the current diagnostic 
algorithm when investigating a patient with acquired demyelinating neuropathy (standard of care, 
SOC) with an alternative diagnostic algorithm which includes VEGF testing and mandatory 
immunofixation as follows, and detailed in figure 1:
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1. Current Standard of care (SOC): SPEP; if positive, immunofixation 
2. Intervention: SPEP, and immunofixation. VEGF testing in electrophysiologically confirmed 
acquired demyelinating polyneuropathy.  
We modelled an incidence cohort of 3,635 patients with an inflammatory polyneuropathy as the 
study population, which we estimated to approximate the annual number of patients referred by 
a GP to neuromuscular clinics with any inflammatory polyneuropathy in the UK. [16]  This estimate 
was based on the demographically similar population and healthcare system of the Netherlands 
as the nearest to the UK (Supplementary Materials IV). Patients transitioned through the decision 
tree according to test accuracy, misdiagnosis and treatment rates (Supplementary Material II). 
We used a time horizon from presentation with polyneuropathy symptoms, until a confirmed, 
correct diagnosis. POEMS syndrome diagnosis is typically between six months and two years, no 
discounting was applied. Input data and sources are described in Supplementary Material III.
Our model estimated the cost associated with each diagnostic pathway, and number of POEMS 
syndrome patients with a correct initial diagnosis. To evaluate cost-effectiveness using the 
incremental cost-effectiveness ratio (ICER); i.e. the added cost per additional correct POEMS 
syndrome diagnosis. We carried out one-way deterministic sensitivity analyses (DSA) and 
probabilistic sensitivity analysis (PSA), as detailed in the Supplementary Material III.
ETHICS
This study was approved by the London School of Hygiene and Tropical Medicine Ethics 
Committee. The retrospective cohort data of which this project became a part, was approved by 
the Health Research Authority and London Queen Square Research Ethics Committee.
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RESULTS
Fifty-five patients of 100 (55%) were initially diagnosed as having CIDP, and eight patients were 
initially diagnosed with other diseases (5= Guillain-Barre syndrome, 1=Monoclonal gammopathy, 
1= Vitamin B12 deficiency, 2= scleroderma). Median waiting time for a CIDP-misdiagnosed 
patient was 14 months (IQR: 7–24), compared to nine months (IQR 6 – 13) for patients directly 
diagnosed with POEMS syndrome; there was no significant difference in symptoms on diagnosis, 
or clinical outcomes between groups (Supplementary Material V).
Cost of CIDP misdiagnosis 
Patients received between one and 10 treatments of IVIG (median 3, IQR: 1-5), and a median of 
180 grams-per-treatment (IQR: 146–347g). The median Ig-cost per patient was £7,650 (IQR: 
£6,216-£14,769) and delivery cost, £12,795 (IQR: £4,265–£21,325). The median total IVIG 
treatment cost per patient with a CIDP misdiagnosis was £20,984 (IQR: £11,809– £30,349). 
If we assume patients misdiagnosed with CIDP (n=55) with missing treatment information (n=15)  
received no treatment, the total costs of CIDP misdiagnosis across our cohort is £808,550 
(average cost £14,701). However, if we assume these patients received treatment in the same 
proportions as the cohort for which treatment information is known (n=40) the total costs of CIDP 
misdiagnoses is £1,111,756 with a median cost of £20,214 per patient (IQR: 11,808 –30,348).1
1 Calculated by multiplying recorded IVIG treatment data (grams per course, number of IVIG courses) by unit costs 
(Supplement I) for each patient, and summing all estimates (£676,2431) and dividing by n (=26)
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Table 1: Costing and cost-effectiveness results 
Costing analysis
Patients with 
CIDP 
misdiagnosis
IVIG Steroids
Plasma 
Exchange
Cost
Cohort n n Cost, £ n Cost, £ n Cost, £ Total, £ Av, £
Conservative – 
assuming patients with 
no treatment info 
(n=15) received no 
treatment
55 38 797,3831 19 2892 6 10,8793 808,550 14,701
Extrapolated – 
assuming patients with 
missing treatment 
information received 
treatment in the same 
proportions as the 
cohort for which 
treatment is known
55 524 1,096,4011 26 3972 8 14,9583 1,111,756 20,214
Cost-effectiveness analysis
Correct diagnoses
Total cost, GBP (incorrect treatment costs, IFIX + 
VEGF screening costs)
Standard of care 12.5 £2,813,462  (£213,107, £98,007)
Intervention 28.1 £2,706,064  (£26,334, £179,584)
Incremental effect and  
costs 
15.6 -£107,398
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Incremental cost 
effectiveness ratio 
Dominates (£6,880 saved for each correct diagnosis)
1. Calculated by multiplying patients receiving IVIG [n] by median IVG treatment cost (£20,214) 
2. Calculated by multiplying patients receiving treatment [n] by cost per course (£1,813.12; Supplement I)
3. Calculated by multiplying patients receiving treatment [n] by cost per course (£15.20; Supplement I)
4. ((38 (patients recorded to receive IVIG)/ 40 (patients with treatment information)) x 55
Cost-effectiveness analysis 
The intervention diagnostic algorithm, in which all patients with acquired demyelinating 
polyneuropathy were screened with VEGF (including SPEP and immunofixation), would save 
£107,398 and result in 15.6 additional POEMS syndrome patients directly diagnosed per year 
across the UK (Table 1). The sensitivity analysis shows that the intervention dominated the SoC 
across uncertainty values (Supplementary Material VI).
DISCUSSION
Our study found that from a cohort of 100 POEMS syndrome patients, 55 were initially diagnosed 
with CIDP. Treatment associated with an initial incorrect CIDP diagnosis led to large, wasted 
healthcare expenditure. Treatment with IVIG alone was estimated to cost £20,984 per POEMS 
syndrome patient incorrectly diagnosed with CIDP, and we estimated that between 69% and 95% 
of misdiagnosed patients received IVIG treatment. When combined with the PLEX and 
corticosteroid treatment costs for patients recorded to have received these, the total wasted 
healthcare expenditure of CIDP misdiagnoses across our 100-patient cohort was between 
£808,550 - £1,111,756. This is a substantial waste of resources, and given the NHS is extremely 
resource constrained, carries a large opportunity cost. Incorrect IVIG treatment for POEMS 
patients may also have resulted in unnecessary harmful side effects. Indirect costs, such as time 
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lost at employment or education, travel costs for treatment, and the emotional and social impacts 
of diagnostic uncertainty were not evaluated in this study and thus the true cost to misdiagnosis 
is likely to be far higher than that calculated here. 
Our cost-effectiveness analysis suggests misdiagnosis and associated costs could be reduced or 
avoided by a change in the diagnostic protocol. Introducing mandatory immunofixation with a 
SPEP for patients presenting with an inflammatory polyneuropathy, and VEGF testing for patients 
with an acquired demyelinating polyneuropathy (most often considered to represent CIDP) could 
immediately lead to annual cost-savings of £107,398 for the NHS. This pathway would require an 
increase in the number of VEGF and immunofixation  tests but would result in a higher number of 
POEMS syndrome patients initially correctly diagnosed and therefore reduced waste expenditure 
for the treatment of incorrect conditions. 
RECOMMENDATIONS 
Routine inflammatory neuropathy screening with SPEP only is not adequately sensitive to detect 
small plasma cell clones. Monoclonal gammopathies that are correctly identified are additionally 
at risk of misinterpretation as a paraproteinaemic neuropathy or coincidental Monoclonal 
Gammopathy of Unknown Significance (MGUS) and thus IVIG treatment remains indicated. This 
study highlights the clinical and economic rationale firstly to test immunofixation in combination 
with SPEP in all cases presenting with inflammatory neuropathy. This is the most sensitive 
measure to identify relevant monoclonal gammopathies which may be associated with the 
neuropathy and require specific treatment. Once neurophysiology is performed,  all cases of  
acquired demyelinating peripheral neuropathy (in which most are considered to be CIDP in the 
outpatients setting), particularly those where IVIG is being considered should receive a VEGF test 
(see figure 1). A significantly raised VEGF at this stage would be a strong indication of POEMS 
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syndrome and thus should prompt thorough exploration for an underlying monoclonal plasma cell 
disorder if not already discovered upon initial serological testing. Mildly elevated VEGF can occur 
rarely in other inflammatory neuropathies and haematological malignancies,[11] and therefore the 
combination of demyelinating neuropathy, significantly raised VEGF, and lambda paraprotein is 
essential to make a definitive POEMS diagnosis. Patients in our retrospective cohort diagnosed 
in less than six months from symptom onset had significantly lower ONLS scores (n=4) compared 
to those diagnosed after six months (n=6) (p<0.05) suggesting delayed diagnosis increases 
neuropathy severity.[5] Implementation of VEGF testing into routine clinical practice should 
correctly identify more POEMS cases from CIDP on initial presentation and avoid ineffective 
immunomodulatory therapy. Early diagnosis will allow for  initiation of POEMS directed therapy 
resulting in improved patient outcomes. The ultimate objective of this newly proposed 
management strategy is to improve patients’ quality of life, and ability to live and work 
independently. 
Page 14 of 41
https://mc.manuscriptcentral.com/jnnp
Journal of Neurology, Neurosurgery, and Psychiatry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
14
REFERENCES
1 Suichi T, Misawa S, Beppu M, et al. Prevalence, clinical profiles, and prognosis of 
POEMS syndrome in Japanese nationwide survey. Neurology 2019;93:e975–83. 
doi:10.1212/WNL.0000000000008062
2 Dispenzieri A. POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and 
management. Am J Hematol 2019;94:812–27. doi:10.1002/ajh.25495
3 Keddie S, D’Sa S, Foldes D, et al. POEMS neuropathy: optimising diagnosis and 
management. Pract Neurol 2018;2:practneurol-2017-001792. doi:10.1136/practneurol-
2017-001792
4 Nasu S, Misawa S, Sekiguchi Y, et al. Different neurological and physiological profiles in 
POEMS syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol 
Neurosurg Psychiatry 2012;83:476–9. doi:10.1136/jnnp-2011-301706
5 Keddie S, Foldes D, Caimari F, et al. The clinical characteristics, risk factors, and 
outcomes of POEMS syndrome: A longitudinal cohort study. Neurol (in print)
6 Curtis L, Burns A. Unit Costs of Health and Social Care 2018. Pers Soc Serv Res Unit 
(University Kent) Published Online First: 2018. 
doi:https://doi.org/10.22024/UniKent/01.02.70995
7 Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: Definitions and long-term 
outcome. Blood 2003;101:2496–506. doi:10.1182/blood-2002-07-2299
8 Jenner W, Klingberg S, Tate JR, et al. Combined light chain immunofixation to detect 
monoclonal gammopathy: A comparison to standard electrophoresis in serum and urine. 
Clin Chem Lab Med 2014;52:981–7. doi:10.1515/cclm-2014-0023
9 Pretorius CJ. Screening immunofixation should replace protein electrophoresis as the 
initial investigation of monoclonal gammopathy: Point. Clin Chem Lab Med 2016;54:963–
6. doi:10.1515/cclm-2015-0699
10 Smith J, Raines G, Schneider HG. A comparison between high resolution serum protein 
electrophoresis and screening immunofixation for the detection of monoclonal 
gammopathies in serum. Clin Chem Lab Med 2018;56:256–63. doi:10.1515/cclm-2017-
0266
Page 15 of 41
https://mc.manuscriptcentral.com/jnnp
Journal of Neurology, Neurosurgery, and Psychiatry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
15
11 Pihan M, Keddie S, D’Sa S, et al. Raised VEGF:High sensitivity and specificity in the 
diagnosis of POEMS syndrome. Neurol - Neuroimmunol Neuroinflammation 2018;5:e486. 
doi:10.1212/NXI.0000000000000486
12 Wang C, Huang X-F, Cai Q-Q, et al. Remarkable expression of vascular endothelial 
growth factor in bone marrow plasma cells of patients with POEMS syndrome. Leuk Res 
2016;50:78–84. doi:10.1016/j.leukres.2016.09.017
13 Misawa S, Sato Y, Katayama K, et al. Vascular endothelial growth factor as a predictive 
marker for POEMS syndrome treatment response : retrospective cohort study. BMJ Open 
2015;11:1–8. doi:10.1136/bmjopen-2015-009157
14 D’Souza AD, Hayman SR, Buadi F, et al. The utility of plasma vascular endothelial 
growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. 
Blood 2011;118:4663–6. doi:10.1182/blood-2011-06-362392.The
15 Nobile-Orazio E, Terenghi F, Giannotta C, et al. Serum vegf levels in poems syndrome 
and in immune-mediated neuropathies. Neurology 2009;72:1024–6. 
doi:10.1212/01.wnl.0000344569.13496.ff
16 Watanabe O, Arimura K, Kitajima I, et al. Greatly raised vascular endothelial growth 
factor (VEGF) in POEMS syndrome. Lancet 1996;347:702.
17 Champan M. UCLH Neuroimmunology and CSF Laboratory User Handbook. 2019. 
18 NHS England. National Demand Management Programme for Immunoglobulin. 
Page 16 of 41
https://mc.manuscriptcentral.com/jnnp
Journal of Neurology, Neurosurgery, and Psychiatry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
1
Early VEGF testing in inflammatory neuropathy 
avoids POEMS syndrome misdiagnosis and 
associated costs
Short title: VEGF testing in POEMS syndrome
ES Marsh1*, S Keddie2*, F Terris-Prestholt1, S D’Sa3, MP Lunn2
*joint co-first authorship
1. Faculty of Public Health and Policy, London School of Hygiene and Tropical 
Medicine, 15-17 Tavistock Place, London, WC1H 9SH, UK 
2. Department of Neuromuscular Disease, National Hospital of Neurology and 
Neurosurgery, Queen Square, London, UK
3. Cancer division, University College London Hospital NHS Trust, UK
Word count: 1,486
Corresponding author
Dr Stephen Keddie
Department of Neuromuscular Disease, National Hospital of Neurology and 
Neurosurgery, Queen Square, London, UK
Email: Stephen.keddie@nhs.net
Page 17 of 41
https://mc.manuscriptcentral.com/jnnp
Journal of Neurology, Neurosurgery, and Psychiatry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
2
Funding
Dr Keddie is funded by a Guarantors of Brain & Association of British Neurologists 
Clinical Training Research Fellowship. 
Professor Lunn is supported by the National Institute for Health Research, University 
College London Hospitals Biomedical Research Centre.
No authors received funding for the purposes relevant to the publication. 
Conflict of interest
No competing interests. 
Page 18 of 41
https://mc.manuscriptcentral.com/jnnp
Journal of Neurology, Neurosurgery, and Psychiatry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
3
ABSTRACT 
Background
Prompt diagnosis and early treatment prevents disability in POEMS syndrome. Delay in diagnosis 
is common with 55% of patients initially incorrectly diagnosed with Chronic Inflammatory 
Demyelinating Polyradiculoneuropathy (CIDP). Patients are often treated with Intravenous 
Immunoglobulin (IVIG) which is both expensive and ineffective in the treatment of POEMS. 
Testing patients with acquired demyelinating neuropathy with serum vascular endothelial growth 
factor (VEGF) more accurately identifies POEMS syndrome than the current standard of care 
(SOC). Incorporating VEGF testing into screening could prevent misdiagnosis and reduce costs.
 
Methods 
We used observed treatment information for patients in the University College London Hospital’s 
(UCLH) POEMS syndrome database (n=100) and from the National Immunoglobulin Database to 
estimate costs associated with incorrect CIDP diagnoses across our cohort. We conducted a 
model-based cost-effectiveness analysis to compare the current diagnostic algorithm with an 
alternative which includes VEGF testing for all patients with an acquired demyelinating 
neuropathy.
 
Results
Treatment associated with an incorrect CIDP diagnosis led to total wasted healthcare 
expenditures of between £808,550 and £1,111,756 across our cohort, with an average cost-per-
POEMS-patient misdiagnosed of £14,701 to £20,214. Introducing mandatory VEGF testing for 
patients with acquired demyelinating neuropathy would lead to annual cost-savings of £107,000 
for the NHS and could prevent misdiagnosis in 16 cases per annum.
Page 19 of 41
https://mc.manuscriptcentral.com/jnnp
Journal of Neurology, Neurosurgery, and Psychiatry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
4
Conclusions
Misdiagnosis in POEMS syndrome results in diagnostic delay, disease progression and significant 
healthcare costs. Introducing mandatory VEGF testing for patients with acquired demyelinaitng 
neuropathy is a cost-effective strategy allowing for early POEMS diagnosis and potentially 
enabling prompt disease-directed therapy. 
BACKGROUND: Prompt diagnosis and early treatment prevents disability POEMS syndrome. 
Delay in diagnosis is common with 55% of patients incorrectly diagnosed with Chronic 
Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). Patients are often treated with 
Intravenous Immunoglobulin (IVIG) which is expensive and more importantly ineffective in the 
treatment of POEMS. Testing patients with acquired demyelinating neuropathy with serum 
vascular endothelial growth factor (VEGF) more accurately distinguishes POEMS from CIDP than 
the current standard of care (SOC). Incorporating VEGF testing into screening could prevent 
misdiagnosis and reduce costs.
 
METHODOLOGY: We used observed treatment information for patients in the University College 
London Hospital’s (UCLH) POEMS syndrome database (n=100) and from the National 
Immunoglobulin Database to estimate costs associated with incorrect CIDP diagnoses across our 
cohort. We conducted a model-based cost-effectiveness analysis to compare the current 
diagnostic algorithm with an alternative which includes VEGF testing for patients with suspected 
CIDP.
 
RESULTS: Treatment associated with an incorrect CIDP diagnosis led to total wasted healthcare 
expenditures of between £808,550 and £1,111,756 across our cohort, with an average cost-per-
POEMS-patient misdiagnosed of £14,701 to £20,214. Introducing mandatory VEGF testing for 
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patients with suspected CIDP would lead to annual cost-savings of £10753,000 for the NHS and 
prevent misdiagnosis in 126 cases.
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INTRODUCTION 
Polyneuropathy Organomegaly Endocrinopathy Monoclonal-protein (M-protein) and Skin 
Changes (POEMS) syndrome is a rare but treatable cause of acquired peripheral neuropathy. 
Patients present with length dependent sensorimotor neuropathy, with mixed axonal and 
demyelinating features on neurophysiology.[1–4] Fifty-five percent of patients with confirmed 
POEMS are initially misdiagnosed as having Chronic Inflammatory Demyelinating 
Polyradiculoneuropathy (CIDP), and are treated with immunomodulatory therapies including 
steroids, intravenous immunoglobulin (IVIG) and plasma exchange (PLEX).[5] IVIG is ineffective  
and costly (approximately £42.50 per gram in 2020), [6] often requires day case or hospital 
inpatient stays and can result in both minor and or severe complications. Diagnostic complexity 
results in a mean median time to POEMS diagnosis of 14 months, by which time over 30% of 
patients require a wheelchair or are bedbound.[5]
POEMS syndrome diagnosis relies on identification of a lambda light chain restricted paraprotein 
in combination with the typical neuropathy as hallmarks of disease.[7] Routine investigations to 
discover a monoclonal protein involve a serum protein electrophoresis (SPEP) and 
immunofixation. We have demonstrated in our UK cohort of 100 patients that the SPEP was 
positive in 55% of cases, and immunofixation in 78%.[5] It is common practice for laboratories to 
perform immunofixation only if a paraprotein is present on SPEP, despite studies indicating the 
superiority sensitivity of immunofixation in detecting smalllow level monoclonal bands missed by 
conventional electrophoresis techniques.[8,9] Although modern high resolution electrophoresis 
has been demonstrated tocan be as sensitive as immunofixation,[10] it is not in widespread use 
and this has not been tested in POEMS syndrome cases which classically manifest small but 
significantly relevant monoclonal gammopathies. The data from our clinical cohortur data 
demonstrates a critical low level critical monoclonal band would not have been detected in 23% 
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of cases byif SPEP methodology only were adopted. The disparity in SPEP and immunofixation 
techniques across laboratories, combined with differences in levels of sensitivity results in such 
tests often being difficult to interpret and rely upon.
Serum Vvascular endothelial growth factor (VEGF) of >1000pg/ml has high sensitivity (100%) and 
specificity (93%) in the diagnosis of POEMS syndrome, particularly when used in combination 
withwhen a demyelinating neuropathy and the lambda light chain paraprotein present together..  
Levels are often very high (median pre-treatment VEGF levels in our cohort was 3594pg/ml), [5] 
The few false positives are often simple to interpret in light of clinical informationand although iron 
deficiency anaemia, infection or chronic hypoxic states raise VEGF,.[11–16] very high levels 
found with a demyelinating neuropathy and lambda light chain are diagnostic.  This room 
temperature stable serum test can be sent to specialist labs for measurement, costing 
approximately £50 per sample.[17] We argue that an immunofixation and VEGF should be part 
of routine testing for patients presenting with an acquired peripheral neuropathy and with slowed 
conduction velocitiesy on nerve conduction studies, particularly in those with suspected CIDP. 
This study aims to add to the evidence base supporting a change in the polyneuropathy diagnostic 
process to include VEGF, uniquely from a cost-perspective. In particular, the study will estimate:
I. The cost of misdiagnosing POEMS syndrome patients with CIDP; and 
II. The incremental cost-effectiveness ratio of a new POEMS diagnostic pathway. 
METHODS
Our sequential cohort (n=100) was taken from the POEMS syndrome database of University 
College London Hospital’s (UCLH) POEMS syndrome database, which includes clinical, 
Page 23 of 41
https://mc.manuscriptcentral.com/jnnp
Journal of Neurology, Neurosurgery, and Psychiatry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
8
diagnostic and treatment data. We collected additional data on IVIG treatment from the National 
Demand Management Programme for Immunoglobulin database. [18]
Costing analysis 
Our The costing analysis focused on comparing the cost of patients directly diagnosed with 
POEMS syndrome, compared with patients diagnosed with POEMS subsequent to an incorrect 
CIDP diagnosis. For each activity leading up to a confirmed POEMS syndrome diagnosis (Figure 
1), we estimated the quantity of resources used and multiplied these by their respective unit costs. 
A list of all costing inputs used is included in Supplementary Material II which presents all inputs 
and model assumptions in this analysis. 
 
As detailed IVIG treatment data, including number of treatments and IVIG quantity prescribed was 
only available for a sub-set of patients (n=26), we used information from the National 
Immunoglobulin Database to estimate the average cost of IVIG treatment-per-patient, and 
combined this with unit costs of plasma exchange and corticosteroids to estimate the total costs 
associated with an incorrect CIDP diagnosis for each patient. By multiplying average cost-per-
POEMS syndrome patient misdiagnosed with CIDP by the number of misdiagnosed patients, we 
estimated the total cost associated with CIDP misdiagnoses across our cohort, following NICE 
guidelines , i.e.that is the costs of the excess activities indicated in the pink shaded box in Figure 
1.
Cost-effectiveness analysis 
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We used decision analytical modelling to compare the cost-effectiveness of the current diagnostic 
algorithm when investigating a patient with acquired demyelinating neuropathy (standard of care, 
SOC) with an alternative diagnostic algorithm which includes VEGF testing and mandatory 
immunofixation as follows, and detailed in figure 1:
1. Current Standard of care (SOC): SPEP; if positive, immunofixation 
2. Intervention: SPEP, and immunofixation. VEGF testing in electrophysiologically confirmed 
acquired demyelinating polyneuropathy.  
We modelled an incidence cohort of 3,635 patients with an inflammatory polyneuropathy as the 
study population, which we estimated to approximate the annual number of patients referred by 
a GP to neuromuscular clinics with any inflammatory polyneuropathy in the UK. [16]  This estimate 
was based on the demographically similar population and healthcare system of the Netherlands 
as the nearest to the UK We modelled a cohort of 4,039 patients as the study population which 
we estimated to approximate the annual number of patients referred by a GP to neuromuscular 
clinics with an inflammatory polyneuropathy in the UK (Supplementary Materials IV). Patients 
transitioned through the decision tree according to test accuracy, misdiagnosis and treatment 
rates (Supplementary Material II). We used a time horizon from presentation with polyneuropathy 
symptoms, until a confirmed, correct diagnosis. POEMS syndrome diagnosis is typically between 
six months and two years, no discounting was applied. Input data and sources are described in 
Supplementary Material III.
Our model estimated the cost associated with each diagnostic pathway, and number of POEMS 
syndrome patients with a correct initial diagnosis. To evaluate cost-effectiveness using the 
incremental cost-effectiveness ratio (ICER); i.e. the added cost per additional correct POEMS 
syndrome diagnosis. We carried out one-way deterministic sensitivity analyses (DSA) and 
probabilistic sensitivity analysis (PSA), as detailed in the Supplementary Material III.
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ETHICS
This study was approved by the London School of Hygiene and Tropical Medicine Ethics 
Committee. The retrospective cohort data of which this project became a part, was approved by 
the Health Research Authority and London Queen Square Research Ethics Committee.
RESULTS
Fifty-five patients of 100 (55%) were initially diagnosed as having CIDP, and eight patients were 
initially diagnosed with other diseases (5= Guillain-Barre syndrome, 1=Monoclonal gammopathy, 
1= Vitamin B12 deficiency, 2= scleroderma). Median waiting time for a CIDP-misdiagnosed 
patient was 14 months (IQR: 7–24), compared to nine months (IQR 6 – 13) for patients directly 
diagnosed with POEMS syndrome; there was no significant difference in symptoms on diagnosis, 
or clinical outcomes between groups (Supplementary Material V).
Cost of CIDP misdiagnosis 
Patients received between one and 10 treatments of IVIG (median 3, IQR: 1-5), and a median of 
180 grams-per-treatment (IQR: 146–347g). The median Ig-cost per patient was £7,650 (IQR: 
£6,216-£14,769) and delivery cost, £12,795 (IQR: £4,265–£21,325). The median total IVIG 
treatment cost per patient with a CIDP misdiagnosis was £20,984 (IQR: £11,809– £30,349). 
If we assume patients misdiagnosed with CIDP (n=55) with missing treatment information (n=15)  
received no treatment, the total costs of CIDP misdiagnosis across our cohort is £808,550 
(average cost £14,701). However, if we assume these patients received treatment in the same 
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proportions as the cohort for which treatment information is known (n=40) the total costs of CIDP 
misdiagnoses is £1,111,756 with a median cost of £20,214 per patient (IQR: 11,808 –30,348).1
Table 1: Costing and cost-effectiveness results 
Costing analysis
Patients with 
CIDP 
misdiagnosis
IVIG Steroids
Plasma 
Exchange
Cost
Cohort n n Cost, £ n Cost, £ n Cost, £ Total, £ Av, £
Conservative – 
assuming patients with 
no treatment info 
(n=15) received no 
treatment
55 38 797,3831 19 2892 6 10,8793 808,550 14,701
Extrapolated – 
assuming patients with 
missing treatment 
information received 
treatment in the same 
proportions as the 
cohort for which 
treatment is known
55 524 1,096,4011 26 3972 8 14,9583 1,111,756 20,214
1 Calculated by multiplying recorded IVIG treatment data (grams per course, number of IVIG courses) by unit costs 
(Supplement I) for each patient, and summing all estimates (£676,2431) and dividing by n (=26)
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Cost-effectiveness analysis
Correct diagnoses
Total cost, GBP (incorrect treatment costs, IFIX + 
VEGF screening costs)
Standard of care 12.59.3
£3,030,6822,813,462  (£213,107158,566, 
£105,80198,007)
Intervention 20.928.1
£2,978,066706,064  (£19,59526,334, 
£193,796179,584)
Incremental effect and  
costs 
11.615.6 -£52,616107,398
Incremental cost 
effectiveness ratio 
Dominates (£4,5306,880 saved for each correct diagnosis)
1. Calculated by multiplying patients receiving IVIG [n] by median IVG treatment cost (£20,214) 
2. Calculated by multiplying patients receiving treatment [n] by cost per course (£1,813.12; Supplement I)
3. Calculated by multiplying patients receiving treatment [n] by cost per course (£15.20; Supplement I)
4. ((38 (patients recorded to receive IVIG)/ 40 (patients with treatment information)) x 55
Cost-effectiveness analysis 
The intervention diagnostic algorithm, in which all patients with suspected CIDPacquired 
demyelinating polyneuropathy were screened with VEGF (including SPEP and immunofixation), 
would save £52,616107,398 and result in 11.615.6 additional POEMS syndrome patients directly 
diagnosed per year across the UK (Table 1). The sensitivity analysis shows that the intervention 
dominated the SoC across uncertainty values (Supplementary Material VIVI).
DISCUSSION
Our study found that from a cohort of 100 POEMS syndrome patients, 55 were initially diagnosed 
with CIDP. Treatment associated with an initial incorrect CIDP diagnosis led to large, wasted 
Commented [EM1]:  20.9
Commented [EM2]:  11.6
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healthcare expenditure. Treatment with IVIG alone was estimated to cost £20,984 per POEMS 
syndrome patient incorrectly diagnosed with CIDP, and we estimated that between 69% and 95% 
of misdiagnosed patients received IVIG treatment. When combined with the PLEX and 
corticosteroid treatment costs for patients recorded to have received these, the total wasted 
healthcare expenditure of CIDP misdiagnoses across our 100-patient cohort was between 
£808,550 - £1,111,756. This is a substantial waste of resources, and given the NHS is extremely 
resource constrained, carries a large opportunity cost. Incorrect IVIG treatment for POEMS 
patients may also have resulted in unnecessary harmful side effects. Indirect costs, such as time 
lost at employment or education, travel costs for treatment, and the emotional and social impacts 
of diagnostic uncertainty were not evaluated in this study and thus the true cost to misdiagnosis 
is likely to be far higher than that calculated here. 
Our cost-effectiveness analysis suggests misdiagnosis and associated costs could be reduced or 
avoided by a change in the inflammatory polyneuropathy diagnostic protocol. Introducing 
mandatory immunofixation with a SPEP and VEGF into the screening tests for patients presenting 
with an inflammatory polyneuropathy, and VEGF testing for patients with an acquired 
demyelinating polyneuropathy (most often suspectedconsidered to repres nt CIDP) with an 
acquired demyelinating polyneuropathy could immediately lead to annual cost-savings of 
£52,615107,398 for the NHS. This pathway would require an increase in the number of VEGF 
and immunofixation  tests, but would result in a higher number of POEMS syndrome patients 
initially correctly diagnosed and therefore less reduced waste expenditure wasted for theon 
treatment for of incorrect conditionsmisdiagnoses. 
RECOMMENDATIONS 
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Routine inflammatory neuropathy screening with SPEP only is not adequately sensitive to detect 
small plasma cell clones. Monoclonal gammopathies that are correctly identified are additionally 
at risk of misinterpretation as a paraproteinaemic neuropathy or coincidental Monoclonal 
Gammopathy of Unknown Significance (MGUS) and thus IVIG treatment remains indicated. This 
study highlights the clinical and economic rationale to use firstly to test immunofixation in 
combination with SPEP in all cases presenting with inflammatory neuropathy. This is the most 
sensitive measure to identify relevant monoclonal gammopathies which may be associated with 
the neuropathy and require specific treatment. Once neurophysiology is performed,  all cases of 
early VEGF testing in all patients presenting with an acquired demyelinating peripheral 
neuropathy (in which most are considered to be CIDP in the outpatients setting), particularly those 
where IVIG is being considered should receive a VEGF test (see figure 1). A significantly raised 
VEGF at this stage would be a strong indication of POEMS syndrome and thus should prompt 
thorough exploration for an underlying monoclonal plasma cell disorder if not already discovered 
upon initial serological testing. Mildly elevated VEGF can occur rarely in other inflammatory 
neuropathies and haematological malignancies,[11] and therefore the combination of 
demyelinating neuropathy, significantly raised VEGF, and lambda paraprotein is essential to 
make a definitive POEMS diagnosis.  compared to standard routine screening, Patients in our 
retrospective cohort diagnosed in less than six months from symptom onset had significantly 
lower ONLS scores (n=4) compared to those diagnosed after six months (n=6) (p<0.05) 
suggesting delayed diagnosis increases neuropathy severity.[5] We believe that Iimplementation 
of VEGF testing into routine clinical practice, for which sensitive identification of a lambda light 
chain associated paraprotein with immunofixation is essential for interpretation, would should 
correctly identify more POEMS cases from CIDP on initial presentation and, avoiding ineffective 
immunomodulatory therapy. Early diagnosis will allow for  and more quickly instigateinitiation of 
POEMS directed therapy resulting in improved patient outcomes. The ultimate objective of this 
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newly proposed management strategy is to improve patients’ quality of life, and ability to live and 
work independently. 
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SUPPLEMENTARY MATERIAL
I. IVIG costing inputs 
Unit cost 
(GBP)
Quantity Cost per course (GBP)
IVIG
Medication cost 42.501 Derived Derived
Delivery costs (personnel and services) 853.00 5 4,265.00
Plasma Exchange 
Drug cost 52.532 213 1,103.12
Delivery cost (personnel and services) 142.00 5 710.00
Corticosteroids
Drug cost4 3.805 4 15.20
1. Cost per kg
2. Octaplas, cost per 200ml
3. 5 treatments of 12ml per kg, 70kg person (4.2 units)
4. Prednisolone (20mg daily for 4 months); alternatively, patients might be prescribed a course of Dexamethasone (6 months @ 4 x 40mg tablets). 
This treatment has been found to have similar outcomes to prednisolone but is much more expensive, and therefore likely used infrequently.
5. Cost per month
Note: All sources included in Supplementary Materials III
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II. Decision-tree model structure 
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III. Costing inputs and model parameter estimates
Parameter
Mean
base case SE
DSA1
lower – 
upper
PSA2
Distribution (α, 
β) Source
Prevalence estimates 
CIDP, as % of patients with inflammatory 
polyneuropathy
7.2% 0.05* 2 - 10 Beta (4,32) Calculated (see IV)
POEMS syndrome, as % of patients with 
inflammatory polyneuropathy
0.8% 0.003* 0.25 - 3.00 Beta (4, 718) Calculated (see IV)
Diagnostic test sensitivity 
SPE 55% 0.05 45 – 65 Beta (54, 45) Keddie et al. [2]
Immunofixation 78% 0.04 69 – 85 Beta (77, 22) Keddie et al. [2]
VEGF 94% 0.03 87 – 98 Beta (82, 5) Keddie et al. [2]
Misdiagnosis rates (on false negative test result)
CIDP 87% 0.04 76 – 94  Beta (54, 8) Estimated from UCLH cohort
Other 13% 0.04 - Beta (8, 54) Estimated from UCLH cohort
Treatment for CIDP misdiagnosis (conservative estimate: assuming patients with no treatment info (n=15) received no treatment)
IVIG 69% 0.06 55 – 80 Beta (37, 17) Estimated from UCLH cohort
Plasma exchange 11% 0.04 - Beta (6, 48) Estimated from UCLH cohort
Corticosteroids 35% 0.06 - Beta (19, 35) Estimated from UCLH cohort
No treatment 27% 0.06 - Beta (15, 39) Estimated from UCLH cohort
Costs
POEMS diagnosis
Procedures 
Blood sample £3.00 - - Deterministic NHS Reference costs [3]
Nerve conduction/ electromyography £189.00 - - Deterministic NHS Reference costs [3]
Bone marrow biopsy £177.00 - - Deterministic NHS Reference costs [3]
Bone lesion £275.84 - - Deterministic NHS Reference costs [3]
PET scan £470.71 - - Deterministic NHS Reference costs [3]
Tests (test, reagent and personnel costs) 
SPEP £16.80 - - Deterministic Personal comms [4]
Immunofixation £44.80 - - Deterministic Personal comms [4]
VEGF £55.00 - - Deterministic UCLH Neuroimmunology Handbook [5]
Bone marrow biopsy processing £290.00 - - Deterministic Personal comms [6]
Consultations
GP appointment £37.00 - - Deterministic 2018 Unit Costs of Health and Social 
Care [7]
Consultant-led first clinic appointment £211.00 - - Deterministic NHS Reference costs [3]
Consultant-led follow-up clinic appointment £221.00 - - Deterministic NHS Reference costs [3]
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Treatment for CIDP misdiagnosis
Drug costs 
IVIG cost per gram £42.50 - £14.17 - 
£127.50
Deterministic 2016 NHS Policy Document [8]
PE (Octaplas, cost per 200ml) £220.63 - - Deterministic Open Prescribing database [9]
Prednisolone (20mg, 30 tablets) £3.80 - - Deterministic Open Prescribing database [9]
Treatment variables
IVIG days per course 5 2.5* 2 – 72 Gamma (4, 1) Gorson et al. 2012 [10]
Number of treatments for per course of PE 1 0.5* 2 – 72 Gamma (4, 1) Gorson et al. 2012 [10]
Number of courses of PE 5 2.5* 1 – 42 Gamma (4, 0) Gorson et al. 2012 [10]
Hospital charges
Outpatient admission for IVIG £853.00 - - Deterministic NHS Reference costs [3]
Outpatient admission for PE £142.00 - - Deterministic NHS Reference costs [3]
1. Deterministic Sensitivity Analysis
2. Probabilistic Sensitivity Analysis 
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IV. Prevalence estimates 
We used CIDP and POEMS syndrome prevalence among patients presenting with an inflammatory polyneuropathy, rather than national estimates, 
to match the starting cohort of the decision-tree. We obtained an estimate of the proportion of polyneuropathy cases presenting to a hospital with an 
inflammatory polyneuropathy [1] ], polyneuropathy and CIDP incidence rates, and CIDP and POEMS prevalence rates [11] from the literature. We 
divided CIDP incidence by our calculated inflammatory polyneuropathy incidence to estimate the proportion of inflammatory polyneuropathy patients 
with CIDP and used the prevalence rate ratio of CIDP to POEMS to approximate the proportion of inflammatory polyneuropathy patients with POEMS 
syndrome in our base-case.
Per 100,000 Incident cases %
National polyneuropathy incidence 77 [1] 40,3911
Inflammatory polyneuropathy incidence (% of polyneuropathy) 3,6352 9.0 [1]
National CIDP incidence 0.5 [11] 2621
National CIDP prevalence 2.8 [11]
National POEMS syndrome prevalence 0.3 [11] 281
CIDP prevalence among patients presenting with an inflammatory 
polyneuropathy 
7.23
POEMS prevalence among patients presenting with an inflammatory 
polyneuropathy
0.84
1. Case calculated by multiplying incidence rate multiplied by UK adult population 
2. Calculation: national polyneuropathy incidence * % polyneuropathy cases that are inflammatory 
3. Calculation: CIDP incidence (262)/ National inflammatory polyneuropathy incidence (3,635)/ *100
4. Calculation: CIDP as % of inflammatory polyneuropathy (7.2%)* prevalence rate ratio POEMS (0.3): CIDP (2.8)
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V. Cohort demographics and outcome analysis 
Variable N
All
(95% CI/ IQR)1
Direct
(95% CI/ IQR)
Indirect - CIDP
(95% CI/ IQR)
Indirect -other
(95% CI / IQR) p value
Descriptive statistics
Cohort size (%) 100 - 37 (28 – 47) 55 (45 – 65) 8.0 (4.0 – 15) -
Males (%) 69 69 (60 – 78) 65 (48 – 79) 71 (57 – 81) 75 (37 -94) -
Age at diagnosis (mean) 100 55 (52 – 57) 55 (50 – 61) 53 (50 – 57) 59 (45 – 73) 0.782
Waiting time
Symptoms to diagnosis, 
months (median)
100 11 (7.0 – 21) 9.0 (6.0 – 13) 14 (7.0 – 24) 8.0 (6.1 – 13) 0.113
Pre-diagnosis
Total no of symptoms 
(mean)
100 7 (3.0 – 12) 7.1 (6.4 – 7.7) 7.1 (6.6 – 7.5) 6.5 (5.0 – 8.0) 0.672
Mobility score (median) 99 3.6 (3.0 – 5.0) 3.0 (1.5 – 5) 4.0 (3.0 – 5.0) 3.5 (3.0 – 5.0) 0.383
Wheelchair/ bedbound 
(%)
99 37 (28 – 48) 36 (20 – 53) 38 (25 – 51) 18 (0.0 – 81) 0.984
ONLS (median) 100 6 (4.0 – 8.0) 5.0 (3.0 – 8.0) 7.0 (4.0 – 9.0) 6.5 (4.0 – 8.5) 0.133
Post-diagnosis
Mobility score (median) 99 1.5 (1.0 – 3.5) 1.5 (1.0 – 3.5) 3.0 (2.0 – 4.0) 3.0 (1.5 – 3.0) 0.103
Wheelchair/ bedbound 
(%)
99 12 (6.4 - 20) 8.3 (0.0 – 17) 16 (6.3 – 26) 0 (0 – 0) 0.263
ONLS5 (median) 52 4.0 (3.0 – 5.0) 3.5 (1.5 – 5.5) 4.0 (2.0 – 5.0) 4.0 (4.0 – 5.0) 0.843
Clinical response (%) 56 65 (52 – 77) 54 (33 – 76) 69 (52 – 86) 100 (100 – 100) 0.264
Haematological response 
(%)
89 48 (38 – 59) 53 (35 – 71) 47 (32 – 61) 33 (0 .0 – 88) 0.644
VEGF response (%) 90 79 (69 – 87) 71 (54 – 87) 82 (70 – 93) 100 (100 – 100) 0.244
Relapse (%) 100 32 (23 - 42) 32 (17 – 48) 35 (22 – 48) 13 (0.0 – 42) 0.404
Mortality (%) 100 12 (6.3 – 20) 13 (2.0 – 25) 13 (3.6 – 22) 0 (0.0 – 0.0) 0.914
Abbreviations: CI=Confidence Interval; IQR=Interquartile Range 
1. 95% CI shown for means or proportions, IQR shown for median values 
2. ANOVA test statistic
3. Kruskal-Wallis H test statistic
4. Likelihood Ratio (LR) Chi-Square test
5. ONLS measured 3 years after treatment completion
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VI. Cost-effectiveness analysis 
Figure 1: Deterministic sensitivity analyses of Incremental Cost-Effectiveness Ratios (ICERs) for Intervention vs Current Standard of Care.
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Figure 1: Current POEMS syndrome diagnostic pathway (left) compared to proposed POEMS diagnostic 
pathway, avoiding incorrect diagnosis 
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